New therapeutic approaches against pulmonary fibrosis

Dongke Yu; Yu Xiang; Tingting Gou; Rongsheng Tong; Chuan Xu; Lu Chen; Ling Zhong; Jianyou Shi

doi:10.1016/j.bioorg.2023.106592

New therapeutic approaches against pulmonary fibrosis

Bioorg Chem. 2023 Sep:138:106592. doi: 10.1016/j.bioorg.2023.106592. Epub 2023 May 6.

Authors

Dongke Yu¹, Yu Xiang², Tingting Gou³, Rongsheng Tong¹, Chuan Xu⁴, Lu Chen⁵, Ling Zhong⁶, Jianyou Shi⁷

Affiliations

¹ Department of Pharmacy, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China; Personalized Drug Therapy Key Laboratory of Sichuan Province, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.
² College of Medicine, University of Electronic Science and Technology, Chengdu 610072, China.
³ State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacology, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
⁴ Department of Oncology, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan 610072, China.
⁵ Department of Pharmacy, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China; Personalized Drug Therapy Key Laboratory of Sichuan Province, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China. Electronic address: llilychen2006@163.com.
⁶ Sichuan Provincial Key Laboratory for Human Disease Gene Study, Center for Medical Genetics, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, University of Electronic Science and Technology, Chengdu 610072, China. Electronic address: zhonglingr@126.com.
⁷ Department of Pharmacy, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China; Personalized Drug Therapy Key Laboratory of Sichuan Province, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China. Electronic address: shijianyoude@126.com.

PMID: 37178650
DOI: 10.1016/j.bioorg.2023.106592

Abstract

Pulmonary fibrosis is the end-stage change of a large class of lung diseases characterized by the proliferation of fibroblasts and the accumulation of a large amount of extracellular matrix, accompanied by inflammatory damage and tissue structure destruction, which also shows the normal alveolar tissue is damaged and then abnormally repaired resulting in structural abnormalities (scarring). Pulmonary fibrosis has a serious impact on the respiratory function of the human body, and the clinical manifestation is progressive dyspnea. The incidence of pulmonary fibrosis-related diseases is increasing year by year, and no curative drugs have appeared so far. Nevertheless, research on pulmonary fibrosis have also increased in recent years, but there are no breakthrough results. Pathological changes of pulmonary fibrosis appear in the lungs of patients with coronavirus disease 2019 (COVID-19) that have not yet ended, and whether to improve the condition of patients with COVID-19 by means of the anti-fibrosis therapy, which are the questions we need to address now. This review systematically sheds light on the current state of research on fibrosis from multiple perspectives, hoping to provide some references for design and optimization of subsequent drugs and the selection of anti-fibrosis treatment plans and strategies.

Keywords: COVID-19; Compound; IPF; Pulmonary fibrosis; Target.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

COVID-19* / pathology
Fibroblasts
Fibrosis
Humans
Lung
Pulmonary Fibrosis* / drug therapy
Pulmonary Fibrosis* / pathology